IL-23 p19 drugs for Psoriatic Arthritis

3 tracked IL-23 p19 drugs in the Psoriatic Arthritis race. The class explanation lives on the IL-23 p19 page; the full indication pipeline across every mechanism is on the Psoriatic Arthritis page.

3 approved / phase 4

Head-to-head evidence: guselkumab vs risankizumab · guselkumab vs tildrakizumab · risankizumab vs tildrakizumab

The roster

← all IL-23 p19 drugs